XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The gene therapy-based vaccine targets mucosal tissues in the gastrointestinal tract, allowing for greater selectivity and targeted delivery compared to traditional vaccines.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

JULY 11, 2021

It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson’s could have their causes here – not to mention depressions and autistic disorders.

Bacteria 52

Bacteria Genetics Scientist Regulation 52

The Pharma Data

JUNE 14, 2023

Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime – a common occurrence in people with cystic fibrosis. This can lead to acute infection, and a person could develop sepsis that requires immediate treatment.

RNA 40

RNA Regulation Scientist Bacteria 40

XTalks

DECEMBER 24, 2020

Focusing on biologics, vaccine development and policy platforms in anticipation of an eventual outbreak is why we’re where we are today in terms of the positive side [of the pandemic].”. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Pandemic Efforts. Diagnostics.

Life Science 111

Life Science Vaccination Vaccine Gene 111